ImpediMed Secures Additional Funding of $5 Million Under Capital Growth Facility, After Increase in June Quarter US Sales

MT Newswires Live
2025/07/16

ImpediMed (ASX:IPD) said that the increase in its US sales in the fiscal fourth quarter qualified it for an additional tranche 2 funding of $5 million under a capital growth facility with SWK Funding, according to a Wednesday Australian bourse filing.

US sales for the June quarter came in at 44 units, rising 100% from the previous quarter and 91% from the year-ago quarter. The total contract value for the fiscal fourth quarter came in at AU$6.3 million, jumping 29% from the prior quarter.

The firm executed an agreement for a five-year $15 million growth capital debt facility with SWK Funding in February. Funds under the facility will be used to support growth and commercialization activities.

Its shares jumped 13% on market close.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10